The current price of BMRN is $56.12 — it has decreased by 1.77% since the previous close. Data as of Nov 5, 2026.
BMRN is down 3.90% over the past week, down 2.47% over the past month and up 6.29% over the past year. The price is below its 200-day moving average of $58.46.
Analysts' average 12-month price target for BMRN is $91.06, which implies 62.26% upside from the current price. Individual estimates range from $59.00 to $122.00.
Of the 28 analysts covering BioMarin Pharmaceutical Inc., 5 rate it a strong buy, 16 rate it a buy and 7 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
BioMarin Pharmaceutical Inc. has a market capitalization of $10.86B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, BioMarin Pharmaceutical Inc. posted earnings of $0.23 per share against an estimate of -$0.04933, beating expectations by 566.25%. Upcoming reports are listed in the earnings calendar.
BioMarin Pharmaceutical Inc. reported revenue of $1.02B in its most recent quarter, which has increased by 32.02% compared with the same quarter a year earlier. Analysts had expected $1.02B.
BioMarin Pharmaceutical Inc. has not paid any dividends over the past year.
Companies most comparable to BioMarin Pharmaceutical Inc. include Vertex Pharmaceuticals Incorporated, Insmed Incorporated, Alnylam Pharmaceuticals, Inc., Ascendis Pharma A/S and BridgeBio Pharma, Inc.
In the latest trading session BMRN moved between $55.97 and $57.99, a range of 3.60% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of BioMarin Pharmaceutical Inc. shows a sell rating today and a strong sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks BMRN has traded between $49.26 and $70.98. The current price is 20.94% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.